SCHEMBL19299523

SCHEMBL19299523

O=Cc1ccccc1OCC(=O)NNC(=S)NC(=O)c1ccco1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 10/20 0.73
MAPT P10636 7/20 0.73
LMNA P02545 6/20 0.73
HTT P42858 6/20 0.73
ALDH1A1 P00352 4/20 0.73
SMN1; SMN2 Q16637 3/20 0.73
TDP1 Q9NUW8 3/20 0.63
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
GAA P10253 4/20 0.55
HSP90AA1 P07900 1/20 0.55
AGTR1 P30556 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.53
POLB P06746 2/20 0.52
KCNH2 Q12809 1/20 0.52
HPGD P15428 1/20 0.51
ATM Q13315 1/20 0.49
CYP2C9 P11712 1/20 0.48
RECQL P46063 1/20 0.48
CRHBP P24387 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19294541 0.85 KDM4E (0.80) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299643 0.84 KDM4E (1.00) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL21416971 0.84 KDM4E (1.00) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299712 0.82 KDM4E (0.76) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299694 0.77 KDM4E (1.00) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299544 0.76 MAPT (0.78) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299656 0.76 KDM4E (0.82) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299518 0.76 KDM4E (0.71) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19294508 0.76 KDM4E (0.81) KDM4EMAPTLMNAHTTALDH1A1
SCHEMBL19299715 0.75 KDM4E (0.82) KDM4EMAPTLMNAHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 KDM4E 2925/4885MAPT 4406/4885LMNA 2478/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 KDM4E 2925/4885MAPT 4406/4885LMNA 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.